plus 4, Billy Ray Cyrus says he reflects his dad in Hallmark movie 'Christmas ... - Artistdirect.com |
- Billy Ray Cyrus says he reflects his dad in Hallmark movie 'Christmas ... - Artistdirect.com
- Hear It Here First!! ZVTK "Zevotek Announces Ionic Bulb TV Ads to Air ... - TMCnet
- Movie Review: 'Nine' - Delaware County Daily Times
- Movie showtimes - Herald-Mail
- Movie review | Twice the chipmunks, half the fun in ’Squeakquel’ - State Journal-Register
| Billy Ray Cyrus says he reflects his dad in Hallmark movie 'Christmas ... - Artistdirect.com Posted: 23 Dec 2009 09:21 PM PST  Billy Ray Cyrus says he reflects his dad in Hallmark movie 'Christmas in Canaan'Wed, 23 Dec 2009 23:13:11 Billy Ray Cyrus, Tim McGraw Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Hear It Here First!! ZVTK "Zevotek Announces Ionic Bulb TV Ads to Air ... - TMCnet Posted: 24 Dec 2009 12:27 AM PST
(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (PINKSHEETS: ZVTK) Zevotek, Inc., (OTCBB: MDXG) MiMedx Group, Inc., (NASDAQ: ONAV) Omega Navigation Enterprises, Inc., (NASDAQ: PDII) PDI, Inc., (NASDAQ: SNTA) Synta Pharmaceuticals, Inc., (NASDAQ: ECLP) Eclipsys Corp. www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com email us!! info@StockMarketingInc.com or call 1-866-583-8960 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (PINKSHEETS: ZVTK - Zevotek, Inc.) LATEST NEWS!! Zevotek Announces Ionic Bulb TV Ads to Air Starting December 28 NEW YORK, Dec 23, 2009 -- Zevotek, Inc., (Pink Sheets:ZVTK) (Frankfurt:T5V1), a worldwide direct marketer and distributor of innovative personal and home care items, today announced that starting December 28, it will air its new 2-minute Ionic Bulb TV infomercial on U.S. cable channels. The Company announced that it is buying TV airtime to run the Ionic Bulb ad about 50 times between December 28, 2009 and January 3, 2010, with the ad expected to appear on FOXNews, Hallmark Movie Channel, History International, DIY Network, Planet Green, SOAPnet and New England Cable News Network. TV viewers of the Ionic Bulb infomercial will have a choice of calling a toll-free number to place orders for Ionic Bulbs or visiting www.newionicbulb.com to place orders online. Commenting on the announcement, Zevotek's CEO, Adam Engel, said, "We have been building the business to launch the Ionic Bulb TV campaign and now we are on the launch pad. I am excited to start airing our infomercial on a variety of popular cable channels. The ads will showcase the Ionic Bulb to a wide range of American TV audiences. I look forward to announcing airtimes for Ionic Bulb ads running next week and for the ads that will run in January on these and other major TV channels." The Ionic Bulb is designed for consumer use by combining the performance features of ionic air cleaning technology with those of a 10,000 hour reduced energy use compact fluorescent light bulb (CFL). Mr. Engel added, "I believe Zevotek's Ionic Bulb is the right product at the right time. Ionic Bulbs deliver the money saving value that U.S. consumers want while improving indoor air quality and helping consumers go green. The Ionic Bulb order is the CFL equivalent of a 100 watt bulb equipped with Zevotek's exclusively licensed ionizing technology." About the Company: Zevotek, Inc. plans to market and sell a range of innovative personal and home care items. Zevotek has a license to sell an energy saving compact fluorescent light bulb (CFL) named the Ionic Bulb. The Company plans to market the Ionic Bulb through TV infomercials, catalogs, magazines and major U.S. retail and specialty stores and the Internet. The Company's new 2 minute Ionic Bulb TV ad is designed to air on national cable channels, local broadcast channels and TV superstations. Zevotek's Ionic Bulb infomercial airs on the Company's www.newionicbulb.com website. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: MDXG - MiMedx Group, Inc.) LATEST NEWS!! MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device --Company adds New Executive to lead Sales & Marketing ATLANTA, Dec 23, 2009 -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG.OB) announced today that it has officially launched its first product, Paradis Vaso Shield(TM). In April 2009, The Food and Drug Administration cleared the Vaso Shield for use as a cover for vessels following anterior vertebral surgeries. The Vaso Shield is a permanent and transparent hydrogel product protected by multiple patents and patent applications, as well as a proprietary manufacturing process. Upon completion of an anterior spinal implant procedure, the physician places the Vaso Shield between the spinal implant site and the vessels and then sutures it to the perivertebral, non-vascular soft tissue to secure the implant. The device is designed to protect the vessels in subsequent anterior revision surgeries. The Company also announced the hiring of a Vice President of Sales and Marketing, Mr. Michael W. Carlton. Mr. Carlton brings an extensive background in the management of orthopedic and vascular implant sales and marketing. Mr. Carlton commented, "I am very impressed with MiMedx Group's two new biomaterials, namely its hydrogel and collagen fiber. These products have the potential to improve patient outcomes and significantly reduce costs. I look forward to joining this very experienced management team and assisting with the growth of MiMedx Group." Parker H. "Pete" Petit, MiMedx Chairman and CEO, also commented, "This is an exciting day for MiMedx Group because it represents the commercialization of our first in a series of new products from our hydrogel material. With the hiring of Mike Carlton, we have added another experienced executive to our team. His expertise and leadership will be instrumental in developing our distribution network for our hydrogel spine products and for our future sports medicine collagen fiber products. We look forward to reporting the progress of our market acceptance and the growth of our revenues from Vaso Shield beginning in our first calendar quarter of 2010." About MiMedx Group, Inc. MiMedx Group, Inc. is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and is in the process of transitioning from a development-focused concern to an operating company focused on sales growth and profitability. The Company's assets include intellectual property protecting a collagen-based technology for augmentation of soft and connective tissue diseases and trauma and intellectual property protecting a novel durable hydrogel technology. The Company has received FDA clearance for its first durable hydrogel product, the Paradis Vaso Shield(TM), indicated for use as a cover for vessels following anterior spinal surgery. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: ONAV - Omega Navigation Enterprises, Inc.) LATEST NEWS!! Omega Navigation Enterprises, Inc. Announces Its Joint Venture Company Megacore Shipping Ltd Will Take Delivery of Newbuilding Product Tankers Pursuant to an Amended Agreement With Hyundai Mipo Dockyard ATHENS, GREECE, Dec 23, 2009 -- Omega Navigation Enterprises, Inc. (NASDAQ: ONAV), a provider of global marine transportation services focusing on product tankers, announced today that it has formed an equal partnership (50/50) joint venture company with Topley Corporation, a wholly owned subsidiary of Glencore International AG (Glencore). The name of the joint venture company is Megacore Shipping Ltd. Companies owned by Omega and the Glencore group have novated their respective original shipbuilding contracts entered into with Hyundai Mipo, consisting in total of 10 newbuilding 37,000 dwt product/chemical carriers (MR1s) (5 vessels each partner), to companies wholly owned by Megacore. This order has now been converted to two 37,000 dwt product/chemical tankers (MR1s) and seven 75,000 dwt. product/oil tankers (LR1s) while one MR1 vessel has been suspended and remains as an option for Megacore to exercise in the future. The original delivery schedule of eight vessels in 2010 and two vessels in the beginning of 2011 has been amended to three vessels in 2010 four in 2011 and two in 2012. The overall aggregate purchase cost based on contract price has remained similar to the original contracts, while the amount of equity that would need to be invested based on vessels assessed fair market values has been reduced. All nine vessels will be owned by companies fully owned by Megacore, with Omega providing the technical, operating and administrative services and ST Shipping (wholly owned subsidiary of Glencore) providing commercial management. The first of these vessels will be delivered during the first quarter of 2010 and has secured a three year time charter with NYK lines which was announced previously. Also, Omega had previously announced financing commitments on its newbuildings and has transferred these commitments to Megacore. Omega President and CEO George Kassiotis commented, "We are very pleased to have entered this joint venture with a very strong partner and thus reinforce the already strong relationship with the Glencore group. Megacore will allow Omega to enjoy significant operating and commercial synergies with one of the largest commodities trading companies in the world. The joint venture will have access to Glencore's global trading network and system cargoes and ST Shipping's commercial chartering experience and will enable us to deploy collectively with our partner a fleet of vessels with significant scale and geographic coverage. Also, the amendment of the newbuilding order has allowed Omega to better manage its capital exposure in this very difficult operating and credit environment. In addition, by spreading the deliveries into 2010, 2011 and 2012, while maintaining the same pre delivery payment terms it allows time for a market recovery and extends out our required cash outlays for the vessels. It is apparent that our 2010 equity requirements have thus been significantly reduced. The conversion into LR1 vessels is also beneficial as the LR1 sector arguably has been the strongest sector in these difficult times both in terms of asset value as well as chartering rates demonstrating the market perception for strong fundamentals based on the increased use of longer haul routes. This off balance sheet structure and revised delivery dates has enabled the Company to shore up its balance sheet and be better able to face these challenging economic times we are in. The LR1 vessels have been contracted at a very high specification and we feel very happy to enjoy such a strong relation and good cooperation with a preeminent shipyard like Hyundai Mipo. Megacore gives both Omega and the Glencore group a very strong platform to build upon going forward." About Omega Navigation Enterprises, Inc. Omega Navigation Enterprises, Inc. is an international provider of global marine transportation services through the ownership and operation of double hull product tankers. The current fleet includes nine double hull product tankers (one through a joint venture) with a carrying capacity of 559,358 dwt all of which are under time charter contracts with an average age of less than three years. In addition to the above mentioned nine newbuilding vessels the Company has also announced the purchase of an additional product tanker with a capacity of 47,000 dwt (through a joint venture) scheduled for delivery in the third quarter 2010. With the addition of these ten vessels, Omega's fleet will expand to 19 product tankers with a total deadweight capacity of 1,252,358 dwt. The Company was incorporated in the Marshall Islands in February 2005. Its principal executive offices are located in Athens, Greece and it also maintains an office in the United States. Omega Navigation's Class A Common Shares are traded on the NASDAQ National Market under the symbol "ONAV" and are also listed on the Singapore Exchange Securities Trading Limited under the symbol "ONAV 50." ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: PDII - PDI, Inc.) LATEST NEWS!! PDI Announces New Pharmaceutical Services Business Win With a Top 5 Pharmaceutical Company PARSIPPANY, N.J., Dec 23, 2009 -- PDI, Inc. (NASDAQ: PDII), a leading provider of sales and marketing support to U.S. health care companies, has been awarded a significant contract sales engagement with a Top 5 pharmaceutical company. This program is expected to generate approximately $6 million in revenue for PDI during the first quarter of 2010 and may extend through the remainder of 2010. "Throughout 2009, the people of PDI have been working very hard to provide unequaled value to our clients," said Nancy Lurker, Chief Executive Officer of PDI, Inc. "The feedback that we continue to receive is that the company is providing high-impact, value-driven service, and we are proud that this is leading to new contracts being awarded to us." The new contract covers an assignment in the primary care and gastroenterology therapeutic areas, utilizing a PDI dedicated sales team. Sales representatives are expected to be in the field in January 2010. "Despite the continued consolidation in the health care industry and the overall anemic economic environment, we are entering into 2010 with renewed confidence and enthusiasm," noted Lurker. "We believe that due to our people and the new processes and enhanced services and tools in which we have invested, PDI is well positioned for continued success in the new year." About PDI PDI provides commercialization services for established and emerging biopharmaceutical companies. The company is dedicated to maximizing the return on investment for its clients by providing strategic flexibility, sales and marketing expertise. For more information, please visit the company's website at www.pdi-inc.com. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: SNTA - Synta Pharmaceuticals, Inc.) LATEST NEWS!! Synta Pharmaceuticals Initiates Phase 2 Clinical Trial of STA-9090 in Gastrointestinal Stromal Tumors (GIST) following failure of Gleevec(R) and Sutent(R) STA-9090 shows encouraging preclinical and clinical results in GIST LEXINGTON, Mass., Dec 23, 2009 -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a novel chemical structure. "Both imatinib (Gleevec(R)) and sunitinib (Sutent(R)) have proven very effective in helping patients with GIST to live longer; however, the majority of patients will eventually experience disease progression despite treatment with both of those molecularly targeted therapies," said George Demetri, M.D., Dana-Farber Cancer Institute. "Once those two standard drugs fail, patients have a poor prognosis and very limited treatment options. Hsp90 inhibition is a promising therapeutic approach for these patients because the mutated kinase proteins that are the cause of resistance to both Gleevec(R) and Sutent(R) depend upon being chaperoned and protected by the function of Hsp90. STA-9090 can potently inhibit the Hsp90 function and disrupt the mutant signaling in multidrug-resistant GIST. Based on the preclinical and early clinical results seen to date, STA-9090 has the potential to unlock the true potential of Hsp90 as a therapeutic target in GIST." Preclinical results related to STA-9090 in GIST were presented by Jonathan Fletcher, M.D., Brigham and Women's Hospital, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in November 2009. "We have shown that as many as eight different secondary KIT Gleevec-resistance mutations can occur in different metastases from a single GIST patient whose disease has progressed after treatment with Gleevec(R), which poses a significant challenge for treating drug-resistant GIST," said Dr. Fletcher. "Importantly, all of these different resistance mutations were still sensitive to STA-9090. In these studies, STA-9090 was also 5-15 fold more potent than 17-AAG, a first-generation, ansamycin-family Hsp90 inhibitor. Additionally, STA-9090 was active against GIST cells that were resistant to 17-AAG." "We and our collaborators have been encouraged by the strong preclinical results for STA-9090 in GIST as well as early clinical results from our solid tumor Phase 1 trials, where STA-9090 has generated objective tumor responses and has been well-tolerated, with the most common adverse events, fatigue and gastrointestinal toxicities, being manageable and reversible," said Vojo Vukovic, M.D., Ph.D., Senior Vice President and Chief Medical Officer, Synta Pharmaceuticals. "A particularly encouraging observation was that a GIST patient on our once- weekly dosing Phase 1 solid tumor study, who experienced disease progression while on multiple prior therapies, including Gleevec(R) and Sutent(R), experienced substantial tumor shrinkage and stabilization of disease following treatment with STA-9090. We are looking forward to working closely with leading GIST investigators to evaluate the potential of STA-9090 to benefit patients with this disease." Synta expects to report data from the ongoing Phase 1 and Phase 1/2 trials and initiate studies in multiple other cancer indications in the first half of 2010. About Synta Pharmaceuticals Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com. ------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: ECLP - Eclipsys Corp.) LATEST NEWS!! Eclipsys Increases KLAS Rankings with Debut of Integrated Pharmacy Solution at No. 4 Result of Focus on Delivering Enterprise Portfolio; Decision Support Solution Ranked "Best in KLAS" for Fourth Straight Year; Sunrise Clinical Manager(TM) Remains No. 2 in Acute Care EMRs ATLANTA, Dec 23, 2009 -- Eclipsys Corporation(R), (NASDAQ:ECLP), The Outcomes Company(R), today announced that the company's focus on delivering an enterprise portfolio of high-quality health information software solutions is reflected in the findings of the 2009 "Top 20 Best in KLAS Award: Software and Professional Services" report (2009 Top 20 Best in KLAS Awards report). With a national spotlight on adoption of electronic medical records (EMRs), Eclipsys' acute care EMR repeated its No. 2 ranking in its category, while the company's integrated pharmacy solution debuted in the No. 4 spot within its segment. In addition, for the fourth straight year, Eclipsys' integrated performance management solution, Sunrise EPSi(TM), received top honors in the Decision Support-Business market segment with a "Best in KLAS" award, and its Budgeting software was named a category leader for the third straight year. "We are honored to continue to be named number one by our clients as reported by KLAS," said Tim Rutledge, Eclipsys' senior vice president of Enterprise Performance Management. "We remain focused on providing healthcare organizations with effective and efficient tools to build in best practices and help them in achieving their business goals. It is abundantly gratifying to continue to grow in market share while attaining distinguished client satisfaction awards." Company's Enterprise Portfolio Reflected in Software Solution Rankings Findings of the KLAS report also state that: -- Eclipsys' Sunrise Clinical Manager(TM) once again ranked No. 2 in the Acute Care EMR market segment. In 2008, Eclipsys moved up to the second spot in this category. According to the KLAS CPOE Digest 2009: Meaningful Use and Physician Adoption report, deep adoption is pivotal to the overarching success of an EMR implementation. The same KLAS report concludes that Eclipsys leads the industry in total physicians live on computerized physician order entry (CPOE) and percentage of its client base using the system. -- Eclipsys' pharmacy solution, Sunrise Pharmacy(TM), which was introduced to the market only three years ago, debuted with a No. 4 ranking in its category. With the second highest percentage among the eight vendors qualified to be ranked in the pharmacy segment, 89 percent of Eclipsys clients would buy the integrated pharmacy solution again. -- Eclipsys Sunrise Patient Financials(TM) saw the biggest year-over-year increase among fully-rated products in the Patient Accounting segment. "Our software solution rankings reflect our company's growth and maturity into a leading enterprise vendor of healthcare information technology," said Jay Deady, Eclipsys' executive vice president of Client Solutions. "Eclipsys offers a truly integrated clinical system, along with the highest CPOE adoption by physicians. Those distinctions, in combination with our second place EMR and a client base that outperforms the industry in composite performance across all CMS Quality Measures are clear proof points of our differentiating ability to help support providers in meeting the expected "meaningful use" objectives of the American Recovery and Reinvestment Act (ARRA) of 2009." ------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Movie Review: 'Nine' - Delaware County Daily Times Posted: 24 Dec 2009 02:43 AM PST NEW YORK (AP) --- Title-wise, the musical "Nine" registers half a digit higher than "8 1/2," the Federico Fellini masterpiece that inspired the stage show that was the source for this new movie version. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Posted: 24 Dec 2009 01:46 AM PST For Thursday through Sunday Movie times listed are those provided as of noon Wednesday and may be revised by theaters at any time.
MARYLAND
REGAL VALLEY MALL STADIUM 16 Valley Mall 301-582-1000 Alvin and the Chipmunks: The Squeakquel (PG) - Thu. - 9:50, 10:30, 11:15 a.m., 12:15, 1, 1:45, 2:45, 3:30, 4:15, 5:15, 6:30, 7:10, 7:45 p.m.; Fri. - 11:15 a.m., 12:15, 1:10, 1:45, 2:45, 3:30, 4:15, 5:15, 6:30, 7:45, 8:50, 10 p.m.; Sat./Sun. - 9:50, 10:30, 11:15 a.m., 12:15, 1:10, 1:45, 2:45, 3:30, 4:15, 5:15, 6:30, 7:45, 8:50, 10 p.m. Avatar (PG-13) - Thu. - 10:30 a.m., 12:30, 2:20, 4:10, 6:10, 8 p.m.; Fri. - 2:20, 6:10, 8:15, 9:50 p.m.; Sat./Sun. - 10:30 a.m., 2:20, 6:10, 8:15, 9:50 p.m. Avatar 3-D (PG-13) - Thu. - 11:30 a.m., 3:10, 7 p.m.; Fri./Sat./Sun. - 11:30 a.m., 3:10, 7:25, 10:50 p.m. The Blind Side (PG-13) - Thu. - 11:15 a.m., 3:40, 6:45 p.m.; Fri./Sat./Sun. - 11:15 a.m., 3:40, 6:45, 9:45 p.m. Brothers (R) - Thu. - 12:50, 3:55, 7:20 p.m. Did You Hear About the Morgans? (PG-13) - Thu. - 11:05 a.m., 2:10, 5:15, 7:45 p.m.; Fri. - 5:15, 7:45, 10:20 p.m.; Sat. - 10:45 a.m., 2:10, 7:45, 10:20 p.m.; Sun. - 10:45 a.m., 5:15, 7:45 p.m. Did You Hear About the Morgans? (PG-13) (Open caption, descriptive audio format)- Fri. - 2:10 p.m.; Sat. - 5:15 p.m.; Sun. - 2:10, 10:20 p.m. Disney's A Christmas Carol in 3-D (PG) - Thu. - 11:35 a.m., 2:05, 5 p.m.; Fri./Sat./Sun. - 12:50 p.m. Invictus (PG-13) - Thu. - Noon, 6:15 p.m.; Fri./Sat./Sun. - 3:45, 9:55 p.m. Invictus (PG-13) (Open caption, descriptive audio format) - Thu. - 3:15 p.m. It's Complicated (R) - Fri.- 11 a.m., 1:45, 3:15, 4:30, 6:15, 7:15, 9:15, 10:15 p.m.; Sat./Sun. - 10, 11 a.m., 1:45, 3:15, 4:30, 6:15, 7:15, 9:15, 10:15 p.m. Nine (PG-13) - Fri. - 1:35, 4:45, 7:35, 10:35 p.m.; Sat./Sun. - 10:15 a.m., 1:35, 4:45, 7:35, 10:35 p.m. Old Dogs (PG) - Thu. - 8:05 p.m. Precious: Based on the Novel "Push" by Sapphire (R) - Thu. - 10:15 a.m., 1:30, 4:30, 7:30 p.m. The Princess and the Frog (G) - Thu. - 10:05, 11 a.m., 12:30, 1:45, 3, 4:20, 5:30, 7, 8 p.m.; Fri. - 12:30, 3, 5:30, 8:15, 10:25 p.m.; Sat./Sun. - 10:05 a.m., 12:30, 3, 5:30, 8:15, 10:25 p.m. Sherlock Holmes (PG-13) - Fri./Sat./Sun. - 11 a.m., noon, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10:50 p.m. The Twilight Saga: New Moon (PG-13) - Thu. - 12:15, 3:45, 6:50 p.m.; Fri./Sat./Sun. - 12:15, 6:50 p .m. Up in the Air (R) - Thu. - 10:45 a.m., 1:25, 4:05, 7:15 p.m.; Fri. - 1:25, 4:05, 7:15, 10:15 p.m.; Sat./Sun. - 10:45 a.m., 1:25, 4:05, 7:15, 10:15 p.m.
PENNSYLVANIA
CARMIKE CINEMA Chambersburg Mall 717-263-0688 Alvin and the Chipmunks: The Squeakquel (PG) - Thu. - 12:30, 2:40, 4:50, 7 p.m.; Fri. - 2:40, 4:50, 7, 9:10 p.m.; Sat./Sun. - 12:30, 2:40, 4:50, 7, 9:10 p.m. Avatar 3-D (PG-13) - Thu. - Noon, 3:30, 7 p.m.; Fri. - 3:30, 7, 10:30 p.m.; Sat./Sun. - Noon, 3:30, 7, 10:30 p.m. The Blind Side (PG-13) - Thu. - 1:25, 4:20, 7:10 p.m.; Fri. - 4:20, 7:10 p.m.; Sat./Sun. - 1:25, 4:20, 7:10 p.m. Did You Hear Abut the Morgans (PG-13) - Thu. - 1:45, 4:35, 7:10 p.m.; Fri. - 4:35, 7:10, 9:45 p.m.; Sat./Sun. - 1:45, 4:35, 7:10, 9:45 p.m. Invictus (PG-13) - Thu. - 1:20, 4:15, 7:10 p.m.; Fri./Sat./Sun. - 10 p.m. It's Complicated (R) - Fri. - 4, 7, 9:50 p.m.; Sat./Sun. - 1, 4, 7, 9:50 p.m. The Princess and the Frog (G) - Thu. - 12:35, 2:50, 5:05, 7:20 p.m.; Fri. - 2:50, 5:05, 7:20, 9:35 p.m.; Sat./Sun. - 12:35, 2:50, 5:05, 7:20, 9:35 p.m. Sherlock Holmes (PG-13) - Fri.- 4, 7, 10 p.m.; Sat./Sun. - 1, 4, 7, 10 p.m. The Twilight Saga: New Moon (PG-13) - Thu. - 1, 4, 7 p.m.
WAYNESBORO THEATRE 75 W. Main St., Waynesboro, Pa. 717-762-7879 The Princess and the Frog (G) - Thu./Fri. - 7 p.m.; Sat./Sun. 1, 7 p.m.
WEST VIRGINIA
BERKELEY PLAZA 7 Berkeley Plaza Shopping Center Martinsburg, W.Va. 304-263-9303 Avatar (PG-13) - Fri. - 5:05, 8 p.m.; Sat./Sun. - 11:05 a.m., 1:45, 4:30, 7:15 p.m. Alvin and the Chipmunks: The Squeakquel (PG) - Fri.- 5, 7, 9 p.m.; Sat./Sun. - 11 a.m., 1, 3, 5, 7, 9 p.m. Did You Hear About the Morgans (PG-13) - Fri. - 5, 7, 9 p.m.; Sat./Sun. - 11 a.m., 1, 3, 5, 7, 9 p.m. It's Complicated (R) - Fri.- 5, 7:05, 9:10 p.m.; Sat./Sun. -10:45 a.m., 1:10, 4, 6:50, 9:10 p.m. The Princess and the Frog (G) - Fri. - 5, 7, 9 p.m.; Sat./Sun. - 11 a.m., 1, 3, 5, 7, 9 p.m. Sherlock Holmes (PG-13) - Fri.- 5, 7:30 p.m.; Sat./Sun. - 10:45 a.m., 1:10, 4, 6:50, 9:10 p.m. Up in the Air (R) - Fri.- 5, 7, 9 p.m.; Sat./Sun. - 11 a.m., 1, 3, 5, 7, 9 p.m.
REGAL MARTINSBURG STADIUM 10 Foxcroft Avenue, Martinsburg, W.Va. 304-264-4056 Alvin and the Chipmunks: The Squeakquel (PG) - Thu. - 10:30, 11:45 a.m., 12:45, 1:45, 3, 4, 5:15, 6:30, 7:30, 8:35 p.m.; Fri. - 11:45 a.m., 12:45, 1:45, 3, 4, 5:15, 6:45, 7:45, 8:55, 10 p.m.; Sat./Sun. - 10:30, 11:45 a.m., 12:45, 1:45, 3, 4, 5:15, 6:45, 7:45, 8:55, 10 p.m. Avatar (PG-13) - Thu. - 11:30 a.m., 3:10, 7 p.m.; Fri./Sat./Sun. - 11:30 a.m., 3:15, 7, 10:15 p.m. The Blind Side (PG-13) - Thu. - 11 a.m., 1:45, 4:30, 7:15 p.m.; Fri./Sat./Sun. - 4:30, 7:30 p.m. Brothers (R) - Thu. - 10 a.m., 12:50, 3:30, 7:30 p.m. Did You Hear About the Morgans? (PG-13) - Thu. - 11 a.m., 1:30, 4, 8 p.m.; Fri. - 1:30, 4, 8, 10:20 p.m.; Sat. - 11 a.m., 4, 8, 10:20 p.m.; Sun. - 1:30, 4, 8 p.m. Did You Hear About the Morgans? (PG-13) (Open captioned/descriptive audio format) - Fri. - 11 a.m.; Sat. - 1:30 p.m.; Sun. - 11 a.m., 10:20 p.m. Invictus (PG-13) - Thu. - 11:15 a.m., 5, 7:45 p.m.; Fri./Sat./Sun. - Noon, 10:15 p.m. Invictus (PG-13) (Open captioned/descriptive audio format) - Thu. - 2 p.m. It's Complicated (R) - Fri. - 1:15, 4:15, 7, 9:35 p.m.; Sat./Sun. - 10:15 a.m., 1:15, 4:15, 7, 9:35 p.m. The Princess and the Frog (G) - Thu. - 11:15 a.m., 1:30, 4:30, 7 p.m.; Fri./Sat./Sun. - 11:30 a.m., 2, 4:15, 7:15, 9:35 p.m. Sherlock Holmes (PG-13) - Fri./Sat./Sun. - 11 a.m., 12:15, 1:50, 3:30, 4:40, 6:30, 7:30, 9:20, 10:20 p.m. The Twilight Saga: New Moon (PG-13) - Thu. - Noon, 3:30, 7:15 p.m. Up in the Air (R) - Thu. - 10:45 a.m., 1:15, 4:45, 7:45 p.m.; Fri./Sat./Sun. - 11:15 a.m., 2:15, 4:45, 7:15, 9:50 p.m.
OPERA HOUSE 131 W. German St., Shepherdstown, W.Va. 304-876-3704 The Informant (R) - Fri. - 5:30 p.m.; Sat. - 8:15 p.m.; Sun. - 2 p.m. Whip It (PG-13) - Fri. - 8:15 p.m.; Sat. - 5:30; Sun. - 5 p.m.
STAR MOVIE THEATRE 137 N. Washington St., Berkeley Springs, W.Va. 304-258-1404 Closed until Jan. 8. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Movie review | Twice the chipmunks, half the fun in ’Squeakquel’ - State Journal-Register Posted: 23 Dec 2009 11:59 PM PST "Alvin and the Chipmunks: The Squeakquel" offers exactly two big laughs for its kiddo target audience — one involves passing gas, the other a shot to the crotch. Since there's a fair amount of time between these two bits of comic invention, young and old alike have ample opportunity to mull over the movie's head-scratching decisions, which, on further review, still leave us with more questions than answers. Namely: 1. Why do the Chipmunks need to go to high school? Early in "Squeakquel," a rodent-related accident lands Dave (Jason Lee) in a full body cast. (Apparently, Lee had a scheduling conflict or a really good note from home, making him unavailable for duty here.) Dave puts the rodents in the care of his slacker cousin Toby (Zachary Levi) and instructs that Alvin, Simon and Theodore go to school. Now we already know that the Chipmunks are smarter than Dave. And at the beginning of "Squeakquel," we see again that they are veritable cash machines capable of rocking the house with ear-bleeding covers of songs old and new. So do chipmunks really need a diploma? And given their size, wouldn't they be safer with the kindergarten crowd? Say what you will about the 2007 "Chipmunk" movie, but at least it had a story. Here, they've basically dropped the Chipmunks into "High School Musical" and, God help us, we'd take the warbling of Zac Efron and Vanessa Hudgens' any day over the sound of processed rodents. 2. If you double the chipmunks, do you double the ... um ... fun? "Squeakquel" introduces us to the Chipettes, three girl chipmunks, whose personalities and singing aspirations mirror the boys. Christina Applegate, Amy Poehler and Anna Faris voice the Chipettes, but you'd never know it because their factory-rendered, high-pitched voices sound fairly identical, completely wasting the talent behind them. 3. Why didn't David Cross have Jason Lee's escape clause (or sense of dignity)? Cross' desperate villain, Ian, returns in "Squeakquel," pretty much doing the exact same thing again, down to the wire-cage imprisonment finale. Ian latches onto the Chipettes as his return to the top, boldly proclaiming that they'll make the world forget about the Chipmunks. OK. Maybe if they were singing porcupines, he'd have a point. But take out the earplugs, Ian, and you won't hear any difference in the novelty acts. 4. Has anyone ever talked to Alvin and the boys about the birds and the bees? Just asking because Alvin, in particular, seems a tad confused. The Chipettes' arrival understandably gets the blood flowing (cue Foreigner's "I Want To Know What Love Is"), but Alvin also seems just a little too interested in hooking up with high school girls. (Even the lunk-headed jocks know something's up and plot revenge.) And the ending? Without revealing too much, expect to hear the pitter patter of little rodent feet in (gulp) the "Threequel." 5. Speaking of which, is it too late to start collecting our loose change now so we can send it along to Fox and stave off the inevitable? Name your price, Mr. Murdoch. We'll form the Facebook group. "Alvin and the Chipmunks: The Squeakquel," a 20th Century Fox release, is rated PG for some mild rude humor. Running time: 89 minutes. One star out of four. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| You are subscribed to email updates from Add Images to any RSS Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
.gif "OBAT KUAT")
.gif)
0 Response to "plus 4, Billy Ray Cyrus says he reflects his dad in Hallmark movie 'Christmas ... - Artistdirect.com"
Posting Komentar